Polyomavirus BK with rearranged noncoding control region emerge in vivo in renal transplant patients and increase viral replication and cytopathology by Gosert, Rainer et al.
T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
ARTICLE
JEM © The Rockefeller University Press  $30.00
Vol. 205, No. 4,  April 14, 2008  841-852 www.jem.org/cgi/doi/
841
10.1084/jem.20072097
        Polyomavirus BK  –  associated nephropathy 
(PVAN) has emerged as the most challenging 
infectious cause of irreversible kidney trans-
plant (KT) failure (  1, 2  ). PVAN is diagnosed in 
up to 10% of KT patients around the world, 
causing premature graft loss in the 6  –  60 mo af-
ter transplant (  3, 4  ). Histologically, progression 
from a mainly cytopathic pattern (PVAN A) to 
extensive cytopathic/infl  ammatory changes of 
interstitial nephritis (PVAN B) is associated 
with increasing graft loss from   <  10 to 50%, ex-
ceeding 80% for PVAN C when tubular atro-
phy and fi  brosis predominate (  5  ). Histological 
studies have demonstrated extensive BKV rep-
lication in the urothelial cell layer (  6  ); how-
ever, unlike in bone marrow transplant patients, 
BKV-associated hemorrhagic cystitis is rarely 
encountered in KT patients, despite high urine 
viral loads (  7  ). The emer  gence of PVAN is 
  remarkable in view of the 50 yr of experience 
in kidney transplantation and the basically 
unchanged high prevalence of BKV infection 
in the general population (  8  –  10  ). The   “  net 
state of immunosuppression  ”   seems crucial 
for PVAN pathogenesis and refl  ects the use of 
more potent immunosuppressive drugs syner-
gizing with other factors, such as older age, 
negative BKV recipient and positive BKV do-
nor status, higher number of HLA mismatches, 
and prior rejection episodes (  7, 11  –  14  ). The role 
of viral determinants is presently unclear. As no 
antiviral drug of proven effi   cacy is available 
(  15  ), current treatment is based on reducing 
immunosuppression to regain immune control 
over BKV replication and disease (  16, 17  ). 
This maneuver bears the risk of rejection and 
entry into a vicious cycle with eventual graft 
loss (  18  ). 
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  Immunosuppression is required for BK viremia and polyomavirus BK  –  associated nephropathy 
(PVAN) in kidney transplants (KTs), but the role of viral determinants is unclear. We exam-
ined BKV noncoding control regions (NCCR), which coordinate viral gene expression and 
replication. In 286 day  –  matched plasma and urine samples from 129 KT patients with BKV 
viremia, including 70 with PVAN, the majority of viruses contained archetypal (ww-) NCCRs. 
However, rearranged (rr-) NCCRs were more frequent in plasma than in urine samples 
(22 vs. 4%; P   <   0.001), and were associated with 20-fold higher plasma BKV loads (2.0   ×   
10  4  /ml vs. 4.4   ×   10  5  /ml; P   <   0.001). Emergence of rr-NCCR in plasma correlated with 
duration and peak BKV load (R  2   = 0.64; P   <   0.001). This was confi  rmed in a prospective 
cohort of 733 plasma samples from 227 patients. For 39 PVAN patients with available 
biopsies, rr-NCCRs were associated with more extensive viral replication and infl  ammation. 
Cloning of 10 rr-NCCRs revealed diverse duplications or deletions in different NCCR subre-
gions, but all were suffi  cient to increase early gene expression, replication capacity, and 
cytopathology of recombinant BKV in vitro. Thus, rr-NCCR BKV emergence in plasma is 
linked to increased replication capacity and disease in KTs. 842 REARRANGEMENTS OF BK VIRUS CONTROL REGION EMERGE IN VIVO | Gosert et al.
respectively (  Table I  , rr-NCCR architecture in samples 
column). The number of patients with rr-NCCR BKV 
in plasma represented a signifi  cant fraction (P   <   0.0005, 
Kolmogorov-Smirnov; see footnote a in   Table I  , Patients 
column) compared with the fraction of patients with rr-
NCCR in urine (P = 0.45, Kolmogorov-Smirnov). The higher 
frequency of patients with rr-NCCR in plasma compared 
with urine was statistically signifi  cant (P   <   0.0001,        2   test; 
see footnote b in   Table I  , Patients column). The same was 
true when the analysis was restricted to patients with 
the histological diagnosis of PVAN in biopsies (  n   = 70; 
rr-NCCR in plasma 35, 50%; ww-NCCR in urine 67, 
96%; P   <   0.0001,        2   test). When we compared the NCCR 
architecture in 129 patients with (  n   = 70) and without 
histologically defi   ned PVAN (  n   = 59;   Table I  , Patients 
column), the detection of rr-NCCR in plasma was signifi  -
cantly associated with a positive biopsy (35 of 70 vs. 9 of 59; 
P   <   0.0001,        2   test). 
  When expressed per sample, ww-NCCR BKVs were de-
tected in the majority of plasma and urine, but rr-NCCRs 
were signifi  cantly more frequent in plasma compared with 
urine samples (64 and 12 of 286, respectively; P   <   0.0001,        2   
test;   Table I  , Samples column). For the diff  erence of 52 sam-
ples (18%), we found discordance between rr-NCCR BKV 
in plasma and ww-NCCR in urine (illustrated for 5 patients 
in   Fig. 1 A  ).   BKV rr-NCCR variants were   associated with 
higher plasma BKV loads compared with ww-NCCR BKV 
(median 4.36   ×   10  5   vs. 1.97   ×   10  4   geq/ml; P   <   0.000002, 
Mann-Whitney   U   test;   Table I  , Samples column). In contrast, 
no association with ww- or rr-NCCR architecture was ap-
parent for urine BKV loads (median 2.89   ×   10  8   vs. 2.56   ×   10  7   
geq/ml; P = 0.098, Mann-Whitney   U   test). However, urine 
BKV loads were on average 3,000-fold (range 100  –  10,000-fold) 
higher than plasma BKV loads. 
To corroborate the association of rr-NCCR and plasma 
BKV loads, we prospectively analyzed 733 serial BKV DNA  –
  positive plasma samples from 227 KT patients, including 57 
cases with documented PVAN (  Table I  ). The results identi-
fi  ed the overall rr-NCCR prevalence rate, ranging from 15% 
per sample to 24% per patient, and confi  rmed the association 
of rr-NCCR with higher median BKV loads (rr-NCCR 
4.59   ×   10  5   geq/ml and ww-NCCR 1.94   ×   10  4   geq/ml; P   <   
0.00002;  Table I ). BKV rr-NCCRs were detected in 113/733 
plasma samples (15%) consisting of ins-NCCR in 11% and 
del-NCCR in 35%, as well as mixtures of ins/ww and del/
ww NCCRs in 13 and 41%, respectively (  Table I  , rr-NCCR 
architecture in samples column). Again, rr-NCCR in plasma 
was signifi  cantly associated with a PVAN-positive biopsy 
(26 of 57 vs. 19 of 141; P   <   0.0001,        2   test).
  We also analyzed 56 BKV-positive urine samples from 
KT patients without concurrent BKV viremia (median, 
14,700 geq/ml; range, 1,000  –  8.9   ×   10  8  ) and found ww-
NCCR BKV in all cases. When examining 264 healthy 
blood donors, BKV was only detected in urine, but not in 
plasma in 26 (9.8%) cases, all of which were of archetype 
ww-NCCR confi  guration (median viral load, 2,600 geq/ml; 
  Outside the KT setting, BKV seems well adapt  ed to the 
human host. BKV asymptomatically infects 60  –  90% of the 
world  ’  s population during childhood and subsequently per-
sists in the renourinary tract (  9, 19  ). After kidney transplanta-
tion, BKV viruria rates increase from 5 to 40%, with the 
percentage of urine viral loads increasing from   <  10  5   to   >  10  7   
genome equivalents (geq)/ml and decoy cell shedding (  1, 5, 
20  ). Renal allograft function is not aff  ected at fi  rst, but one 
third of patients are at high risk of progressing to BKV vire-
mia and overt PVAN (  1, 21  ). In patients with PVAN under-
going allograft nephrectomy, plasma BKV loads drop to 
undetectable levels with a half-life of   <  2 h, indicating that 
BKV viremia is essentially derived from replication in renal 
allografts (  22  ). Accordingly,   >  99% of plasma BKV loads in 
steady state are replaced every day, refl  ecting loss of at least 
10  6   renal tubular epithelial cells to release progeny virus (  22  ). 
After reduced immunosuppression, plasma BKV loads decline 
over 7  –  13 wk (  22  ), and antiviral cellular immune responses 
directed against early and late viral proteins become detect-
able in the peripheral blood (  23, 24  ). Thus, BKV load in 
plasma is widely accepted as a marker of onset and resolution 
of PVAN (  1, 17  ). 
  Polyomavirus genomes are circular dsDNA of 5 kb con-
sisting of the noncoding control region (NCCR) with the 
origin of replication and promoter/enhancer functions con-
trolling expression of the early proteins, large and small 
T-antigen, and the late agnoprotein and the capsid proteins 
VP1-3 (  25  ). BKV strains excreted in urine of immunocom-
petent individuals have been reported to be of archetype 
(ww-) NCCR architecture. Upon propagation of BKV in 
tissue culture, however, ww-NCCR BKV are readily re-
placed by BKV variants with genetically rearranged (rr-) 
NCCR, whereas other areas of the BKV genome remain 
unchanged (  26  –  28  ). Because of NCCR hypervariability in 
tissue culture, identifi  cation of archetype ww-NCCR re-
quires direct analysis of BKV genomes from biological sam-
ples e.g., by PCR amplifi  cation and cloning. PCR studies of 
PVAN biopsies identifi  ed rr-NCCR in approximately one 
fourth of BKV strains, indicating that rr-NCCR BKV were 
not necessary for histological disease (  29  –  31  ). Given the rapid 
dynamics of BKV replication and the close correlation of 
plasma BKV load with PVAN, we compared the occurrence 
of rr-NCCR variants in BKV-positive plasma and urine sam-
ples, and investigated the functional consequences. 
    RESULTS   
  rr-NCCRs are associated with higher plasma BKV load 
  The NCCR architecture was analyzed by PCR in 129 KT 
patients, including 70 with PVAN-positive biopsy results, 
providing a total of 286 same day  –  matched plasma and urine 
samples (  Table I  ).   The majority of patients had ww-NCCR 
detectable in plasma (  n   = 85; 66%) and in urine (  n   = 119; 
92%;   Table I  , Patients column). rr-NCCRs consisted of 
larger and shorter amplicons representing insertions (ins-)
NCCR in 14%, deletions (del-)NCCR in 42%, and mix-
tures of ins/ww- and del/ww-NCCR in 6 and 38%, JEM VOL. 205, April 14, 2008 
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indeed, emerged from initial ww-NCCR BKV strains after 
prolonged viremia (  Fig. 1 B  ). Regression analysis revealed 
that the time to fi  rst rr-NCCR emergence correlated with 
peak plasma viral load (P   <   0.000001;   Fig. 1 C  ). The linear 
and the quadratic regression models largely overlapped be-
tween BKV loads of 5.5  –  7.5 log10 geq/ml. However, the 
convex shape of the quadratic regression model provided a 
better fi  t of the overall data, suggesting that higher peak 
plasma BKV loads overproportionally increased the risk of 
rr-NCCR emergence. Accordingly, rr-NCCRs were de-
tectable in patients with high peak plasma BKV load of 6.5 
log10 geq/ml after   <  4 mo, whereas 100-fold lower vire-
mia (4.5 log10) required   >  7 times as long. The data indi-
cated that duration and peak replication favored the change 
from ww- to rr-NCCR BKV variants as the majority spe-
cies. The only case where rr-NCCR BKV was already pre-
sent in the fi  rst BKV-positive plasma sample was a patient 
retransplanted after allograft loss and nephrectomy after 
PVAN. This observation was intriguing, and suggested 
that impaired BKV-specifi  c cellular immunity is not only 
critical for curtailing BKV replication (  23  ), but possibly 
range, 1,000  –  64,900). We concluded that rr-NCCR BKV 
variants appeared more frequently in plasma than in urine 
in viremic KT patients, and were then associated with sig-
nifi  cantly higher plasma BKV loads. In contrast, the day-
matched urine BKV loads were generally 3,000-fold higher 
than the corresponding plasma BKV loads, regardless of 
the NCCR architecture. This observation, together with 
the discordance of rr- and ww-NCCR architecture in day-
matched plasma and urine samples provided quantita  tive 
and molecular evidence that renal tubular epithelial cells 
and urothelial cells in ureters and bladder, indeed, refl  ected 
diff  erent viral replication compartments in immuno  suppressed 
KT patients, thereby extending previous histopathology 
data (  6  ). 
  rr-NCCR BKV replace ww-NCCR BKV with persisting viremia 
  In preceding plasma samples from patients with rr-NCCR 
variants, we detected ww-NCCR BKV in all but one case. 
A detailed analysis of 35 PVAN patients with rr-NCCR 
(  Table I  ) revealed that plasma rr-NCCR BKV variants, 
  Table I.      Architecture of BKV NCCR in plasma and urine of KT patients 
Patients Samples rr-NCCR architecture 
  in samples
Matched 
  plasma + urine
NCCR P value    a   NCCR P  value    d   
ww rr ww rr ins ins/ww del del/ww
Plasma   n   = 129 85    b   44      b     <  0.0005   n   = 286 222    c   64    c   9 4 27 24
Percentage (%) 66 34 78 22 14 6 42 38
PVAN   n   = 70 35 35
Percentage (%) 50 50   <  0.0005
Viral load (geq/ml) 1.97   ×   10  4      e   4.36    ×   10  5      f      <  2   ×   10       6 
25th percentile 3.93   ×   10  3 6.59    ×   10  4 
75th percentile 1.72   ×   10  5 5.47    ×   10  6 
Urine   n   = 129 119    b   10    b   =0.45 274    c   12    c   -255
Percentage (%) 92 8 96 4 0 16 42 42
PVAN   n   = 70 67 3 =0.5
Percentage (%) 96 4
Viral load (geq/ml) 2.89   ×   10  8      e   2.56    ×   10  7      f   =0.098
25th percentile 1.66   ×   10  7 2.84    ×   10  6 
75th percentile 3.38   ×   10  9 6.93    ×   10  8 
Consecutive plasma 
  (2005  –  2006)
  n   = 227 172 55 =0.004   n   = 733 620 113 12 15 39 47
Percentage (%) 76 24 85 15 11 13 35 41
PVAN   n   = 57 31 26   <  0.002
Percentage (%) 54 46
Viral load (geq/ml) 1.94   ×   10  4 4.59    ×   10  5    <  2   ×   10       6 
25th percentile 4.55   ×   10  3 3.51    ×   10  5 
75th percentile 1.58   ×   10  5 3.04    ×   10  6 
  a  Kolmogorov-Smirnov Goodness-of-Fit test (one-sided).
  b,  c       2   test (two-sided), plasma rr-NCCR versus urine rr-NCCR. P   <   10      4 .
  d,  e  ,  f Mann-Whitney   U   test  (one-sided).
  e  Plasma ww-NCCR versus urine ww-NCCR. P   <   10      4 .
  f  Plasma rr-NCCR versus urine rr-NCCR. P   <   0.002. Viral load is given as median.844 REARRANGEMENTS OF BK VIRUS CONTROL REGION EMERGE IN VIVO | Gosert et al.
  rr-NCCR are diverse and without corresponding 
changes in VP1 
  To characterize the architecture of rr-NCCR in more de-
tail, we sequenced 5 ins-NCCR and 5 del-NCCR from 10 
diff  erent patients with PVAN. Insertions consisted of partial 
duplication of the P-Q region, whereas deletions preferen-
tially aff  ected the Q-R-S region (  Fig. 3  ).   Thus, NCCR re-
arrangements changed transcription factor-binding sites and 
enhancer elements, but no common feature was apparent 
(Fig. S1, available at http://www.jem.org/cgi/content/full/
jem.20072097/DC1). Sequencing of the antigenic determi-
nants of VP1 revealed BKV serotype I and IV in 8 and 2 rr-
NCCR variants, respectively. In all cases, the VP1 sequences 
were identical with the one detected when the majority spe-
cies were of archetype ww-NCCR (  Fig. 3 B   and Fig. S2). 
Thus, NCCR rearrangements were not linked to changes in 
VP1 serotype. 
  rr-NCCRs are suffi  cient to increase early reporter 
gene expression 
  To investigate functional eff  ects of rr-NCCR in regard to 
early and late gene expression, we constructed a bidirectional 
reporter vector phRG, having the red fl  uorescent protein 
(RFP) and GFP in the same positions as the early and late 
genes in the circular BKV DNA genome (  Fig. 3 A  ). Human 
embryonic kidney (HEK) 293 cells were transfected and as-
sayed for red and green fl  uorescence. The expression patterns 
became detectable as early as 1 d after transfection (dat) and re-
mained stable for at least 10 d of observation (all scored at 2 dat; 
  Fig. 3 B  ). Archetype ww-NCCR conferred a strong late gene 
expression (green signal) and a relatively weak early gene ex-
pression (red signal, at     1/10 of the green signal). In contrast, 
all rr-NCCRs increased early gene expression by two- to sev-
enfold, and decreased late gene expression, irrespective of 
insertion or deletion architectures. Simple deletions or duplica-
tions had eff  ects similar to more complex ones, suggesting that 
the architectural context and not the mere number of tran-
scription factor binding sites might be relevant. We therefore 
generated two NCCR variants by in vitro mutagenesis that 
refl  ected small insertions or deletions of the natural NCCR 
sequences. Both ins(P24-37)NCCR and del(R8-18)NCCR 
aff  ected early and late gene expression in a manner similar to 
in vivo –  occurring variants ins(23.1)NCCR or del(15.10)NCCR 
(  Fig. 3 B  ). As NCCR expression might be aff  ected by host cell 
type and diff  erentiation, we tested two prototype rr-NCCRs 
(del 5.3, ins 7.3) in addition to the ww-NCCR (ww 1.4) in 
cells known to support BKV replication in vitro (Vero mon-
key kidney cells and human umbilical cord vein endothelial 
cells) and in vivo (primary human renal proximal tubular epi-
thelial cells [RPTECs]). We found that the expression patterns 
for all three NCCR prototypes were similar in all tested cell 
types (  Fig. 3 C  ). Northern blot analysis and RNA protection 
experiments at 2 dat indicated that NCCR-driven RNA ex-
pression correlated with RFP and GFP signals (unpublished 
data). To exclude vector-mediated positional eff  ects on gene 
expression, the del(5.3)NCCR was inserted in reverse 
also for recurrence of BKV replication and direct emer-
gence of rr-NCCR variants (  24, 32  ). 
  rr-NCCR BKV are associated with histological 
disease progression 
  Comparing PVAN histology in needle biopsies from 39 
patients with either rr-NCCR (  n   = 21) or ww-NCCR (  n   = 
18) in plasma, we found that the percentage of surface with 
tubules showing cytopathic changes staining positive for large 
T-antigen (LTag) was signifi  cantly higher in cases with rr-
NCCR BKV variants in plasma compared with ww-NCCR 
BKV (median 15%, mean 26.6   ±   29.4 vs. median 3.5%, mean 
11.3   ±   17.1; P = 0.03; Mann-Whitney   U   test). In addition, 
cytopathically altered areas from patients with rr-NCCR 
BKV were more likely to have lymphocytic infl  ammatory 
infi  ltrates compared with ww-NCCR BKV (60 vs. 23.07%, 
respectively; P = 0.04, Mann-Whitney   U   test). Finally, de-
tection of rr-NCCR in plasma was associated with PVAN 
pattern B (  Fig. 2 B  ), whereas ww-NCCR more readily pre-
sented as PVAN pattern A (  Fig. 2 A  ; 15/21 vs. 6/18, respec-
tively; P = 0.03, Fischer  ’  s exact test).   
    Figure 1.         BKV NCCR in plasma and urine of KT patients.   (A)  Discor-
dance of NCCR majority species in matched urine (U) and plasma (P) sam-
ples shown for 5 patients. Nested PCR targeting the BKV NCCR was 
resolved on 2% agarose-tris acetate, pH 8.0, electrophoresis gels and 
stained with ethidium bromide. NCCR ww, archetype; del, deletion, ins, 
insertion, bp, base pairs of marker. (B) Emergence of rr-NCCR in consecu-
tive plasma shown for patient 2 (del-NCCR) and 5 (ins-NCCR) resolved as 
in A. (C) Time to rr-NCCR detection and peak plasma BKV load in consecu-
tive plasma samples from 35 KT patients analyzed by linear and quadratic 
regression. Fine line, linear regression; bold line, quadratic regression; 
dashed lines, 90% confi   dence  interval.   JEM VOL. 205, April 14, 2008 
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  rr-NCCR increase BKV replication and cytopathology 
in vitro 
  To directly examine the impact of rr-NCCR on BKV gene 
expression and replication, we generated recombinant BKV 
strains by cloning each of the indicated 10 rr-NCCR, as well 
as the archetype ww-NCCR, into the genomic backbone of 
the BKV Dunlop strain. At 3 dat of recombinant BKV 
DNA into Vero cells, DNase-protected BKV DNA loads 
in supernatants were 1  –  3 log10 higher viral loads for all 
10 recombinant rr-NCCR BKV strains compared with 
ww(1.4)NCCR (  Fig. 5 A  ).   More detailed analysis revealed 
that supernatants of del(5.3)NCCR BKV  –  transfected cells 
had 3 and 1.5 log10 higher viral loads at day 3 and 7, respec-
tively, and a pronounced cytopathic eff  ect at day 21 com-
pared with ww(1.4)NCCR BKV (  Fig. 5 B  ). Western blot 
analysis of the transfected Vero cells demonstrated that LTag 
expression occurred     12  –  24 h earlier in del(5.3)NCCR 
BKV, with a corresponding acceleration of VP1 expression 
compared with ww(1.4)NCCR BKV strains (  Fig. 5 C  ). 
When Vero cell supernatants were harvested 7 dat and seeded 
for infection of primary RPTECs, we observed that more 
cells were infected by the recombinant del(5.3)NCCR BKV 
than by the ww(1.4)NCCR BKV, with corresponding super-
natant viral loads being 100-fold higher (unpublished data). 
Immunofl  uorescence staining of RPTECs at day 4 after in-
fection identifi  ed a correspondingly higher number of in-
fected cells in del(5.3)NCCR BKV –   than in the ww(1.4)NCCR 
BKV  –    infected cells (  Fig. 5 D  , green stain; 10  ×   magnifi  ca-
tion). Moreover, LTag preceding expression of the late agno 
gene could be observed at the single-cell level (  Fig. 5 D  , 
  orientation relative to RFP and GFP (phRG-del[5.3R]). 
Transfection phRG-del(5.3R) into the diff  erent cell types re-
vealed strong early but weak late gene expression, as observed 
for del(5.3)NCCR, but in opposite colors (  Fig. 3 C  , compare 
column 2 and 4). We concluded that rr-NCCR BKV variants 
were of diverse architecture, but all increased early gene ex-
pression in vitro as a common hallmark. 
  To investigate whether the genomic NCCR rearrange-
ment still allowed for modulatory eff  ects in trans, we exam-
ined the responses of the bidirectional reporter vector 
phRG to BKV LTag, steroids, and agnoprotein expression, 
which have been reported to positively and negatively regu-
late NCCR expression (  33  ). As shown for the prototype 
ins(7.3)NCCR (  Fig. 4  ), increasing LTag expression as de-
tected by Western blot raised late gene expression by 5-fold 
within 24 h (green,   Fig. 4 A  ).   Because glucocorticoid response 
elements are present in BKV NCCR, we examined whether 
steroid treatment modulated gene expression in Vero monkey 
kidney cells that, unlike HEK293, expressed functional gluco-
corticoid receptors. Treatment with dexamethasone at 10       6   M 
increased early and late gene expression from the ww-
NCCR (3-fold), and to lesser degrees, also from the del(5.3)- 
(2.5-fold) and ins(7.3)-NCCR (2-fold;   Fig. 4 B  ). When BKV 
agnoprotein was cotransfected, both early and late reporter 
gene expression signals were     10-fold reduced for all 3 
NCCRs (  Fig. 4 C  ). Collectively, these results indicated 
that rr-NCCR consistently increased early gene expression 
relative to archetype ww-NCCR, but still remained suscepti-
ble to modulatory eff  ects in trans conveyed by LTag, steroids, 
or agnoprotein. 
    Figure 2.         Histological patterns of PVAN in kidney biopsies.   (A) Haematoxylin/eosin stain of a representative histological fi  eld showing PVAN 
pattern A consisting of focal viral cytopathic changes with little infl  ammation or tubular atrophy. Immunohistochemistry of LTag expression using the 
cross-reacting monoclonal anti  –  SV40 T-antigen Ab-2 and peroxidase-conjugated anti  –  mouse. Enlargement of the indicated area is shown. (B) Haema-
toxylin/eosin stain of a representative histological fi  eld showing PVAN pattern B with extensive viral cytopathic changes and infl  ammatory infi  ltrates. 
Immunohistochemistry of LTag expression using the cross-reacting monoclonal anti-SV40 T-antigen Ab-2 and peroxidase conjugated anti – mouse. 
Bars: (A and B) 200   μ  m; (A and B, insets) 100   μ  m.     846 REARRANGEMENTS OF BK VIRUS CONTROL REGION EMERGE IN VIVO | Gosert et al.
    Figure 3.         BKV NCCR architecture and expression pattern in cell culture.   (A) Architecture of archetype ww-NCCR in BKV genome, with arbitrarily 
denoted linear blocks (number of base pairs) O(142)-P(68)-Q(39)-R(63)-S(63) and position of primers (arrows). RFP, RFP for early genes; GFP, GFP for late 
genes; bG-pA,      -globin polyA; Hyg, hygromycin resistance; Amp, ampicillin resistance. (B) Architecture of rr-NCCR clones and gene expression pattern in 
HEK293 at 2 dat. ins, insertions corresponding to duplications of the numbered base pairs; del, deletions, denoted by gaps and nucleotides. VP1-Type, 
serotype; n.a., not applicable because generated by in vitro mutagenesis; Confl  uence, showing phase contrast; Early, red fl  uorescence; Late, green fl  uores-
cence; Expression level, percentage of green and red fl  uorescence  –  positive cells normalized to GFP-positive cells of phRG-ww(1.4) bearing the archetype 
ww-NCCR. (C) NCCR-driven early (E) and late (L) gene expression in different cell types. HEK293, monkey kidney cells (Vero), human umbilical vein endo-
thelial cells (HUVECs), and primary RPTECs were transfected with phRG-bearing archetype ww(1.4)NCCR, del(5.3)NCCR, ins(7.3)NCCR, and del(5.3R)NCCR, 
which contained the del(5.3)NCCR in reverse orientation relative to RFP and GFP (results as above). Numbers indicate fold expression level for 
del(5.3)NCCR (green, late) and ww(1.4)NCCR (red, early), arbitrarily set to 1. (B and C) Mean of three independent experiments. Error bars represent the 
mean   ±   the SD.     JEM VOL. 205, April 14, 2008 
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LTag red nuclear stain, arrows in 40  ×   magnifi  cation; agno 
green cytoplasmic stain) and VP1 expression (not depicted). 
Thus, we concluded that rr-NCCR were suffi   cient to confer 
increased early gene expression, replication, and cytopathol-
ogy to recombinant BKV in vitro. 
    DISCUSSION   
  The failing balance between BKV replication and antiviral 
immune control is the hallmark of PVAN in KT recipients 
(  17, 24  ). Viral factors have been postulated to contribute to 
PVAN pathogenesis, but determinants, rates, and mecha-
nisms remained speculative (  7, 31  ). In this study, we took 
advantage of BKV viremia as a noninvasive marker of renal 
allograft involvement and provide evidence that the NCCR 
is a relevant viral determinant of BKV replication rate and 
PVAN pathogenesis. Although BKV variants with rr-NCCR 
had previously been detected in immunocompromised 
patients (  29  –  31, 34, 35  ), we show for the fi  rst time that 
rr-NCCR BKV variants emerge and replace archetype 
ww-NCCR BKV as majority species in vivo in 24% of KT 
patients with persisting BKV viremia and in 50% of patients 
with PVAN. The time to emergence of rr-NCCR BKV 
variants in plasma was inversely correlated to peak plasma 
BKV loads. Thus, duration and level of BKV replication 
increased the risk of rr-NCCR BKV emergence. Compared 
with ww-NCCR strains, rr-NCCR variants were associated 
with 20-fold higher median plasma BKV loads, a higher 
probability of a histologically confi  rmed disease, and in-
creased viral cytopathology and infl  ammatory presentation 
in these patients. 
  Our in vitro studies revealed complex rr-NCCR emerg-
ing in vivo without identifi  able common alterations. How-
ever, using a novel bidirectional reporter gene replicon that 
exactly recapitulated the polyomavirus NCCR genome ar-
chitecture relative to early and late gene organization, we 
could demonstrate that all rr-NCCR augmented early gene 
expression compared with ww-NCCR, while decreasing 
late gene expression. Nevertheless, rr-NCCR remained re-
sponsive to up- and down-regulation by LTag-, agnoprotein, 
and most notably steroids, a clinically defi  ned risk factor of 
BKV replication and PVAN (  1, 36, 37  ). It has been proposed 
that rr-NCCR change critical transcription factor binding 
sites in the ww-NCCR (  38  ), but the diff  erences between 
various deletions and insertions did not reveal a common 
alteration. Clearly, further work is needed to unravel the 
complex molecular organization of BKV NCCR-mediated 
gene expression. 
  We demonstrate that rr-NCCR increased viral early gene 
expression and accelerated viral replication in vitro. The re-
combinant rr-NCCR BKV strains yielded 1  –  3 log10 geq/ml 
higher viral loads in tissue culture compared with archetype 
ww-NCCR BKV. Detailed analysis indicated an     24 h ear-
lier LTag expression with corresponding eff  ects on VP1 ex-
pression, a shorter lag phase reducing the BKV generation 
time from     3 to     2 d, with prominent cytopathology by 
day 21. Thus, rr-NCCRs associated with higher plasma BKV 
    Figure 4.         Modulation of early and late gene expression.   (A)  West-
ern blot detecting LTag in HEK293 cells stably expressing BKV LTag with 
monoclonal anti-SV40 and anti  –  mouse coupled to horseradish peroxidase 
at day 5 after transfection. Cells were transfected with phRG7.3 in the 
presence of Tetracycline (Tet). After 1 d, Tet was replaced by the indicated 
concentrations. Phase contrast (a  –  e), RFP (f  –  j), and GFP (k  –  o) expression 
in the presence of decreasing amounts of Tet (repression of LTag at 
1,000 ng/ml Tet, maximum expression of LTag at 0 ng/ml Tet). Bar, 
400   μ  m. (B) Effect of steroid treatment on early (RFP) and late (GFP) gene 
expression in Vero cells. -, absence; +, presence of 10      6   M  dexametha-
sone. Cells were analyzed at 2 dat. (C) Effect of agnoprotein expression on 
early (RFP) and late (GFP) gene expression in Vero cells. Cells were ana-
lyzed at 2 dat. (A  –  C) Mean of three independent experiments. Error bars 
represent the mean   ±   the SD. 848 REARRANGEMENTS OF BK VIRUS CONTROL REGION EMERGE IN VIVO | Gosert et al.
(  27  ), similar to other viruses (  39  ). Because BKV replication 
requires LTag with its DNA binding and helicase functions, 
some genomic rearrangements, and especially   deletions of 
ori or LTag binding sequences, are likely to   gene  rate defec-
tive NCCR penalized by negative selection. Conversely, 
NCCR rearrangements conferring increased early gene ex-
pression outcompete archetype ww-NCCR BKV strains by 
increased replication capacity, a phenomenon termed posi-
tive selection (  39  ). We noted that NCCR rearrangements 
were unevenly distributed, being less frequent in the vicinity 
of the early gene promoter (typically sparing the origin of 
replication and LTag-binding sites), consisting of partial du-
plication rather than deletions. In contrast, deletions were 
loads and accelerated pathology in KTs were suffi   cient to in-
crease replication capacity and cytopathology of recombinant 
rr-NCCR BKV in tissue culture. 
  The molecular mechanisms leading to NCCR rearrange-
ments in a DNA virus at such high frequency are intriguing 
and as yet unclear. Unlike RNA virus replication generating 
mutant progeny by lack of proof-reading, DNA virus repli-
cation is widely considered a process of high fi  delity, par-
ticularly for viruses that rely on recruiting host cell DNA 
polymerases, such as polyomaviruses. The dependence on 
time and peak plasma BKV load shown here suggests that per-
sistent high-level replication of the circular BKV genome and 
its associated errors may be crucial for rr-NCCR emergence 
    Figure 5.         Replication of recombinant rr-NCCR BKV in cell culture.   (A)  Quantifi  cation of DNase-protected BKV load of rr-NCCR variants in Vero cell 
supernatants collected at indicated times after transfection. Viral load measurements for all 10 recombinant rr-NCCR BKV variants in Vero cells at 3 dat. 
Time course for archetype ww, ww(1.4)NCCR BKV; del, del(5.3)NCCR BKV). The data display a mean of three independent transfections determined in trip-
licate. Error bars represent the mean   ±   SD. (B) Cytopathology of the corresponding cell cultures at 21 dat by phase-contrast microscopy. (C) Western blot 
was performed with polyclonal anti-LTag, anti-VP1, and anti  –  rabbit conjugated to peroxidase, respectively. Tubulin was detected with monoclonal mouse 
anti-tubulin and peroxidase-conjugated anti  –  mouse. VP1, VP1 capsid protein; Tub, tubulin; at, after transfection. Samples were harvested at indicated 
times (hours) after transfection. Molecular weight of proteins is shown in kilodaltons. (D) Infection of primary RPTECs. Vero cell supernatants were har-
vested 7 dat and seeded onto RPTECs. Immunofl  uorescence for LTag (early gene, red) and agnoprotein (late gene, green) was performed on day 4 after 
infection using the monoclonal anti-SV40 LTag visualized with anti  –  mouse Alexa Fluor 568 and polyclonal rabbit anti-agno detected by anti  –  rabbit Alexa 
Fluor 488, respectively. Arrows indicate early LTag-positive staining cells without late agnoprotein staining. Cell nuclei are stained with DRAQ5 (blue). 
Bars: (B) 200   μ  m; (D, 10  ×  ) 200   μ  m; (D, 40  ×  ) 50   μ  m.     JEM VOL. 205, April 14, 2008 
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pression might provide an extended window for cytotoxic 
immune recognition in immunocompetent hosts, which is 
lacking in immunosuppressed KT patients, as well as in tissue 
culture. LTag as a target of cellular immunity has been fi  rst 
identifi  ed in experimental SV40 models (  47  ), in healthy indi-
viduals (  48  ), and, more recently, in peripheral blood of KT 
patients with declining BKV viremia (  23  ). The late capsid 
protein VP1 is also a known target of antiviral immunity, 
particularly for neutralizing antibodies. As VP1 expression is 
closely linked to virion assembly and host cell lysis, anti-
VP1  –  directed CD8-T cells may develop their impact at a 
later stage of the viral life cycle than anti-LTag CD8-T cells 
(  23  ). We speculate that immune surveillance is likely to be 
more stringent for renal tubular epithelial cells than for the 
urothelial cells, as with other mucosal surfaces. This notion 
is also supported by the strong infl  ammatory response evolv-
ing in the infected renal tubulus and its virtual absence in 
the heavily BKV replicating transitional cell layer in KT 
patients. We therefore hypothesize that cellular immunity 
represents a key barrier to rr-NCCR BKV emergence, ren-
dering less well replicating archetype ww-NCCR BKV 
evolutionarily more successful in immunocompetent host 
populations (  Fig. 6  ) (  39  ).   
  In summary, our study underlines that genetic plasticity 
of evolutionarily conserved DNA viruses can be observed 
in vivo in situations permitting unchecked high-level replica-
tion, as in immunocompromised hosts, thereby causing in-
creased cytopathic damage. In KT patients, rr-NCCR BKV 
emergence is a marker of prolonged viral replication and is 
specifi  cally associated with more advanced PVAN histology. 
The role of cellular immunity and the prognostic information 
of rr-NCCR BKV regarding KT function or graft loss has to 
await properly designed prospective studies. 
more frequent toward the late gene expression, removing 
Q-R-S sequences. Interestingly, we did not encounter any 
poorly replicating rr-NCCRs, as had been reported in previ-
ous studies not related to kidney transplantation (  38, 40, 41  ). 
Although these studies support the principle notion that re-
arrangements as a consequence of replication can also gener-
ate defective NCCRs, our results are in line with the fact that 
we targeted by PCR emerging rr-NCCR majority species 
that had been positively selected in these immunosuppressed 
KT patients. 
  The rapid emergence of rr-NCCR BKV variants with 
higher replicative capacity in immunosuppressed KT patients 
is reminiscent of rr-NCCR generation in tissue culture (  26, 
27, 42  ), and is in striking contrast to the stable colonization of 
the world  ’  s population with archetype ww-NCCR BKV 
strains that do not replicate as well (  43, 44  ). Indeed, our on-
going analysis of BKV seropositive healthy blood donors de-
tected asymptomatic BKV viruria in 9.8%, with ww-NCCR 
in all cases. This is in line with earlier reports implicating urine 
as a relevant source of BKV transmission and persistence 
around the world (  7, 45  ). The discordance of rr-NCCR 
BKV in plasma and ww-NCCR BKV in urine in immuno-
suppressed KT patients argues that emergence of rr-NCCR 
in vivo is at least partially defi  ned by host cell properties, i.e., 
the diff  erence between renal tubular epithelial cells and 
urothelial cells. A precedent for the role of host cells is docu-
mented in tissue culture where rr-NCCR emergence re-
quired a longer time in human umbilical vein endothelial 
cells compared with Vero or in HEK293 cells (  26, 27, 42  ). 
Histopathology studies demonstrated in KTs that renal tubu-
lar epithelial cells, as well as in the urothelial cells support 
BKV replication (  6, 46  ), but both host cell types diff  er in ana-
tomical location, function, diff  erentiation and organization as 
single cell layer versus multicellular transitional cell layer, re-
spectively. However, a higher rr-NCCR replication capacity 
in renal tubular epithelial cells may not play out to the same 
extent in the urothelial cells of ureter and bladder because 
urine BKV loads were, on average, 3,000-fold higher than 
plasma BKV loads independent of ww- or rr-NCCR archi-
tecture. We therefore conclude that the selective advantage 
of a higher replication capacity may not be operative to the 
same extent in the urothelial cell compartment. Diff  erent, 
not mutually exclusive, hypotheses may account for this cell 
type phenomenon: (a) activation of early gene expression is 
similar between ww- and rr-NCCR BKV in urothelial cells; 
(b) less LTag is needed to recruit replication factors in con-
tinuously dividing urothelial cells; and (c) ww-NCCR strains 
are reactivated fi  rst and saturate susceptible target cells. 
  Thus, we suggest that antiviral immunity is another 
signifi  cant barrier that is lacking in tissue culture, as well as 
in profoundly immunosuppressed KT patients. Because in-
creased early gene expression appears as a common feature of 
rr-NCCR, cellular immunity directed against early gene en-
coded epitopes may be the important factor limiting emer-
gence of rr-NCCR BKV in the general immunocompetent 
population. The rr-NCCR  –  mediated increase in LTag ex-
    Figure 6.         Emergence of rr-NCCR in the immunocompromised host.  
Naturally transmitted BKV with archetype ww-NCCR genome (black 
circles) undergo insertion and deletion errors during replication generating 
rr-NCCR genomes (red tagged circles). BKV rr-NCCR with increased early 
gene expression and corresponding higher replication capacity are elimi-
nated in immunocompetent host, but outcompete ww-NCCR BKV in 
immunodefi  cient hosts. LT, LTag; VP1, capsid protein 1.     850 REARRANGEMENTS OF BK VIRUS CONTROL REGION EMERGE IN VIVO | Gosert et al.
PCR using primer pairs 5  –  6 and 7  –  8 and pTRE2hyg as template were 
joined in a PCR reaction containing primer pair 5  –  8. The amplifi  cation 
product was digested with AvrII and BamHI, followed by ligation into 
AvrII  –  BamHI-digested pTRE2hyg to yield phyg. Next, BamHI  –  MluI-
cleaved dsRed2 (pdsRed2-C1; BD Biosciences) and ClaI- and SalI-digested 
EGFP (pEGFP-N1; BD Biosciences) were ligated into BamHI  –  SalI  –
    restricted pTRE2hyg to obtain pTREdsRed-EGFP. Next, the BamHI  –  SalI 
dRed2-EGFP fragment was ligated into phyg cleaved with the same en-
zymes to yield phdsRed-EGFP. In the fi  nal step, the AseI  –  EcoRV      -globin 
fragment, blunt ended with T4 polymerase, was subcloned into pGEM-
3Zf+ (Promega) to yield pGEMglobin. This plasmid was cleaved with 
SacI  –  XbaI, and the resulting fragment was ligated into phdsRed-EGFP 
digested with SacI  –  SpeI to obtain phRG. In phRG-NCCR plasmids, the 
expression of RFP (early) and GFP (late) is under control of the inserted 
BKV NCCR. NCCR sequences were amplifi  ed from patient material by 
nested PCR using primer pairs 9  –  10 and 11  –  12. The MluI  –  BssHII-cleaved 
amplicon was ligated into phRG digested with the same enzymes. The plas-
mids phRGinsP24-37 and phRGdelR8-18 were generated from the arche-
type ww-NCCR by a duplication of P24-37 or a deletion of R8-18, 
respectively, by SOE. The two DNA fragments were generated from 
phRGww by PCR using primer pairs 11  –  13 and 14  –  12 (P24-37) or 11  –  15 
and 16  –  12 (R8-18), respectively, and joined in a PCR reaction containing 
primer pair 11  –  12. The amplifi  cation products were ligated into MluI  –
  BssHII-digested phRG, as described. To construct recombinant BKV 
strains, the SacI fragment containing the NCCR was replaced in pBKV 
Dunlop plasmid (American Type Culture Collection [ATCC] 45025) bear-
ing the full-length genome sequence (  50  ). A synthetic linker (primer 17  –  18) 
was ligated into SacI-cleaved pGEM3-Zf+ to yield pGEMSacIlinker. 
The NCCR released from the indicated phRGww, ins, and del constructs by 
MluI  –  BssHII digest was ligated into pGEMSacIlinker cleaved with the same 
enzymes. Finally, the SacI NCCR fragment was ligated into SacI-restricted 
pBKV to generate the respective recombinant pBKVww-, ins-, and del-
NCCR. pCMVAgno encodes the agnoprotein sequence in the pRC/CMV 
(Invitrogen). The entire agno sequence was amplifi  ed from patient material 
by PCR using primer pair 19  –  20. The amplifi  cation product was cleaved 
with BamHI and NotI, followed by ligation into pRC/CMV digested with 
the same enzymes. The integrity of all plasmid constructs was confi  rmed 
by sequencing. 
  Cell lines.     HUV-EC-C (ATCC; CRL 1730) were grown in Kaighn  ’  s 
FK12 medium (  51  ). HEK293 (ATCC CRL1573) and Vero76 cells (ATCC 
CRL1587) were cultured in Dulbecco  ’  s modifi  ed Eagle  ’  s medium (DMEM) 
containing 10% FBS. Primary RPTECs (Cambrex) were propagated in Re-
nal Epithelial Cell Medium (Cambrex). Infection of RPTECs was performed 
as previously described (  52  ). HEK293 cells stably expressing BKV LTag 
were generated by cotransfection of pTET-Off   (BD Biosciences) and 
pTRELTag. Cells were selected and maintained in DME containing 10% 
FBS in the presence of 500   μ  g/ml Geneticin (G418; Invitrogen), 1.5   μ  g/ml 
Puromycin (Sigma-Aldrich), and 1   μ  g/ml Tetracycline (Sigma-Aldrich). 
Transfection of BKV genomes into Vero76 cells was initiated by cleavage of 
pBKV plasmid DNAs with BamHI, followed by relegation of the diluted 
DNA. Transfection of cells was performed at 60  –  80% confl  uency in 12-well 
plates and was achieved as specifi  ed by the manufacturer using Lipofectamine 
2000 or LTX (RPTEC; Invitrogen) at a DNA/Lipofectamine ratio of 0.8:1. 
Transfection of HUV-EC-C was performed with Transpass D1 reagent 
(NEB) according to the manufacturer  ’  s instructions at a DNA/Transpass D1 
ratio of 1.2:1. Medium was replaced after 3  –  6 h. 
  Western blot.     Cells were lysed in RIPA-buff  er (150 mmol/liter NaCl, 50 
mmol/liter Tris-HCl, pH 8.0, 1% NP-40, 0.5% deoxycholate, 0.1% SDS, and 
protease inhibitors [Roche]). Cell lysates were separated by SDS-PAGE and 
electrotransferred onto 0.2-  μ  m nitrocellulose membranes (Whatman). Mem-
branes were blocked with phosphate-buff  ered saline containing 5% nonfat dry 
milk, incubated with monoclonal mouse anti-SV40 T-antigen, Ab-2 (1:800; 
Calbiochem), polyclonal rabbit anti-LTag or anti-VP1 (both 1:2,500), or 
    MATERIALS AND METHODS   
  Patients.     We characterized BKV NCCR in 1,019 plasma and 342 urine 
samples from 412 KT patients. Day-matched plasma and urine samples were 
obtained from KT patients as part of the prospective BKV study protocol 
approved by the University of Maryland Transplant Center. BKV loads had 
been determined by real-time PCR in same day  –  matched plasma and urine 
samples (  n   = 286 from 129 patients, including 70 patients with PVAN). The 
NCCR architecture was determined retrospectively on specimens stored at 
     20  °  C. PVAN was graded based on the Banff   classifi  cation, as recom-
mended by Hirsch et al. (  17  ), as follows: PVAN A, minimal to mild viral cy-
topathic changes (cy1+  –  cy2+), insignifi  cant infl  ammatory infi  ltrates (  <  i1+), 
tubular atrophy (  <  ct1+), or fi  brosis  (  <  ci1+); PVAN B, viral cytopathic 
changes scoring from mild to severe (cy2+  –  cy4+) and signifi  cant infl  amma-
tory infi  ltrates scoring from moderate to severe (i1+  –  i3+), but only mild tu-
bular atrophy (  ≤  ci2+) and mild fi  brosis (  ≤  ci2+); PVAN C, moderate to 
severe tubular atrophy (ct3+) and interstitial fi  brosis (ci2+  –  ci3+), variable 
scores for cytopathic changes (cy1+  –  cy4+), and for infl  ammatory infi  ltrates 
(i1+  –  i3+) (  17  ). During the years 2005 and 2006, an additional 733 consecu-
tive BKV DNA  –  positive plasma samples from 227 patients, including 57 
with PVAN, had been submitted for BKV testing to the Molecular Diagnos-
tics Laboratory of the Division of Diagnostics, which is an accredited quality 
controlled laboratory (EN ISO) of the University of Basel (www.zid.ch). 
If the samples had detectable BKV loads, BKV NCCR sequences were am-
plified as an independent confirmatory assay to confirm BKV specificity. 
Patients with suffi   cient sampling density defi  ned as   >  6 consecutive plasma 
samples collected over   >  12 wk were identifi  ed (  n   = 35, PVAN in 28) to ana-
lyze the dependence of rr-NCCR emergence on time and plasma viral load. 
NCCR architecture was examined in 56 KT patients (median age 44 yr; 
range 17  –  66 yr; 52% female) with urinary BKV shedding, but without con-
current BKV viremia. As controls, we examined BKV in urine and plasma 
of 264 healthy blood donors (median age 46 yr; range 18  –  67 yr; 49% female; 
IRB approval 267/06). 
  BKV load and NCCR analysis.     BKV DNA was quantifi  ed after DNA 
extraction from 200   μ  l plasma, urine, or cell culture supernatant using a com-
mercial kit (QIAmp; QIAGEN) and a previously described real-time PCR 
protocol (  1  ). NCCR amplifi  cation used a standard nested PCR approach 
with the outer primer pairs BKTT5 5     -GAGCTCCATGGATTCTTC-3      
and BKTT6 5     -CCAGTCCAGGTTTTACCA-3      and the inner primer 
pair BKTT7 5     -CCCTGTTAAGAACTTTATCCATTT-3      and BKTT8 
5     -AACTTTCACTGAAGCTTGTCGT-3     . The PCR products were com-
pared after 2%TAE-agarose gel electrophoresis with ww-NCCR controls, 
and excised for sequence analysis, if indicated. Dilution series of increasing 
ratios of rr-NCCR versus ww-NCCR and cloning into plasmids indicated 
that the sensitivity of detecting minority species in NCCR mixtures by the 
PCR protocol was as low as 5%. Patients were scored as bearing rr-NCCR 
when one or multiple samples showed rr-NCCR. Samples containing rr-
NCCR or mixtures of rr- and ww-NCCR (  Table I  , rr-NCCR architecture 
  in samples column) were scored as rr-NCCR. 
  Plasmids and primers.     In pTRELTag the cDNA coding for the LTag of 
BKV is under control of a tetracycline-controlled transactivator-dependent 
promoter. The intron of the LTag was removed by gene splicing by overlap 
extension (SOE) (  49  ). Two DNA fragments were generated using primer 
pairs 1  –  2 (Fig. S3, available at http://www.jem.org/cgi/content/full/
jem.200712097/DC1) and 3  –  4 and DNA extracted from a BKV-positive 
urine as template. The two DNA fragments were subsequently joined in a 
PCR reaction containing primer pair 1  –  4. The amplifi  cation product was 
digested with ClaI and NheI, followed by ligation into ClaI  –  NheI-digested 
pTRE2pur (BD Biosciences). The dual-reporter vector phRG contains 
hygromycin selectable marker, the enhanced GFP and RFP dsRed2 occurs 
in opposite directions with both mRNAs, followed by the same      -globin 
polyA sequence. Plasmid phRG was generated in a three-step procedure. 
First, the tetracycline response element/minimal CMV promoter cassette 
was deleted from pTRE2hyg by SOE. Two DNA fragments generated by JEM VOL. 205, April 14, 2008 
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antiserum directed against BKV-agnoprotein (1:800) (  51  ). The secondary 
antibodies were conjugated with Alexa Fluor 568 or 488 (1:500; Invitrogen). 
Nuclei were labeled in blue with DRAQ5 (Biostatus). 
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For categorical values, Fisher  ’  s exact test or        2   test were used. Nonparamet-
ric tests were used to compare values lacking normal distribution (Mann-
Whitney   U   test, Wilcoxon) where appropriate. All tests were two-sided, 
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